CYP17A1
Basic information
Region (hg38): 10:102830531-102837472
Previous symbols: [ "CYP17" ]
Links
Phenotypes
GenCC
Source:
- congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency (Supportive), mode of inheritance: AR
- 46,XY disorder of sex development due to isolated 17,20-lyase deficiency (Supportive), mode of inheritance: AR
- congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Adrenal hyperplasia, congenital, due to 17-alpha-hydroxylase deficiency | AR | Endocrine; Genitourinary; Oncologic | Individuals may not necessarily manifest with adrenal crisis, but mineralocorticoid excess may result in severe hypokalaemic hypertension, and awareness may allow preventive measures and treatment (eg, including glucocorticoids and mineralcorticoid antagonists); Treatment of genitourinary anomalies, as well as related hypogonadotrophic hypogonadism (eg, with hormone replacement therapy, as well as surgery in some individuals), can be beneficial; Due to risk of malignancy, gonadectomy may be indicated in genotypic males | Endocrine;Genitourinary; Oncologic | 4288776; 6039879; 4303304; 5456802; 999330; 6976525; 2843762; 2026124; 1648117; 2808364; 7629254; 8855840; 9360545; 9326943; 9177409; 11549685; 14671162; 16121340; 18559916; 20170344; 21823532; 22452398; 21550081; 22954317 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (58 variants)
- Deficiency of steroid 17-alpha-monooxygenase (30 variants)
- 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete (8 variants)
- Congenital adrenal hyperplasia (4 variants)
- CYP17A1-related disorder (3 variants)
- 17,20-lyase deficiency, isolated (1 variants)
- 17-alpha-hydroxylase/17,20-lyase deficiency, combined partial (1 variants)
- Breast cancer, susceptibility to (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CYP17A1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 188 | 191 | ||||
missense | 16 | 27 | 49 | 94 | ||
nonsense | 20 | 24 | ||||
start loss | 3 | |||||
frameshift | 20 | 15 | 35 | |||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 12 | |||||
splice region | 1 | 20 | 21 | |||
non coding | 76 | 21 | 105 | |||
Total | 63 | 61 | 56 | 266 | 23 |
Highest pathogenic variant AF is 0.0000460
Variants in CYP17A1
This is a list of pathogenic ClinVar variants found in the CYP17A1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
10-102830536-G-GA | Congenital adrenal hyperplasia | Uncertain significance (Jun 14, 2016) | ||
10-102830572-G-A | Deficiency of steroid 17-alpha-monooxygenase | Uncertain significance (Jan 12, 2018) | ||
10-102830635-G-T | Deficiency of steroid 17-alpha-monooxygenase | Uncertain significance (Jan 13, 2018) | ||
10-102830637-G-T | Deficiency of steroid 17-alpha-monooxygenase | Uncertain significance (Jan 13, 2018) | ||
10-102830705-G-A | Conflicting classifications of pathogenicity (Dec 05, 2023) | |||
10-102830705-G-C | Likely benign (Mar 19, 2022) | |||
10-102830708-G-A | Likely benign (Mar 22, 2023) | |||
10-102830708-G-T | Inborn genetic diseases | Uncertain significance (Mar 20, 2023) | ||
10-102830714-C-G | Uncertain significance (Aug 17, 2023) | |||
10-102830714-C-T | Likely benign (Sep 28, 2019) | |||
10-102830716-C-T | Uncertain significance (May 01, 2021) | |||
10-102830720-C-T | Likely benign (Jan 25, 2024) | |||
10-102830726-T-C | Likely benign (Apr 06, 2023) | |||
10-102830737-C-A | Uncertain significance (Sep 24, 2021) | |||
10-102830741-G-A | Deficiency of steroid 17-alpha-monooxygenase | Conflicting classifications of pathogenicity (Oct 30, 2023) | ||
10-102830742-C-T | Deficiency of steroid 17-alpha-monooxygenase | Likely pathogenic (May 09, 2023) | ||
10-102830743-G-A | Deficiency of steroid 17-alpha-monooxygenase | Pathogenic/Likely pathogenic (Dec 18, 2023) | ||
10-102830746-C-T | Inborn genetic diseases | Uncertain significance (Apr 28, 2022) | ||
10-102830750-G-T | Likely benign (Oct 31, 2021) | |||
10-102830761-TGAAAGAGTC-T | Deficiency of steroid 17-alpha-monooxygenase • 17-alpha-hydroxylase/17,20-lyase deficiency, combined complete | Pathogenic (Mar 23, 2024) | ||
10-102830771-G-A | Deficiency of steroid 17-alpha-monooxygenase | Likely benign (Dec 14, 2023) | ||
10-102830776-G-A | Likely benign (Oct 08, 2021) | |||
10-102830780-G-C | Likely benign (Feb 15, 2021) | |||
10-102830786-C-T | Likely benign (Oct 24, 2021) | |||
10-102830789-G-A | Likely benign (Dec 20, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CYP17A1 | protein_coding | protein_coding | ENST00000369887 | 8 | 7003 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.000263 | 0.985 | 125709 | 0 | 39 | 125748 | 0.000155 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.24 | 219 | 277 | 0.791 | 0.0000162 | 3337 |
Missense in Polyphen | 80 | 107.32 | 0.74545 | 1292 | ||
Synonymous | -0.0109 | 114 | 114 | 1.00 | 0.00000701 | 1002 |
Loss of Function | 2.16 | 9 | 19.2 | 0.468 | 9.92e-7 | 226 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000181 | 0.000181 |
Ashkenazi Jewish | 0.000107 | 0.0000992 |
East Asian | 0.000544 | 0.000544 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000144 | 0.000141 |
Middle Eastern | 0.000544 | 0.000544 |
South Asian | 0.000231 | 0.000229 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Conversion of pregnenolone and progesterone to their 17- alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty. {ECO:0000269|PubMed:22266943}.;
- Disease
- DISEASE: Adrenal hyperplasia 5 (AH5) [MIM:202110]: A form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short adult stature. Four clinical types: 'salt wasting' (SW, the most severe type), 'simple virilizing' (SV, less severely affected patients), with normal aldosterone biosynthesis, 'non-classic form' or late- onset (NC or LOAH) and 'cryptic' (asymptomatic). {ECO:0000269|PubMed:10720067, ECO:0000269|PubMed:11549685, ECO:0000269|PubMed:11836339, ECO:0000269|PubMed:12466376, ECO:0000269|PubMed:14671162, ECO:0000269|PubMed:1515452, ECO:0000269|PubMed:1714904, ECO:0000269|PubMed:1740503, ECO:0000269|PubMed:19793597, ECO:0000269|PubMed:24140098, ECO:0000269|PubMed:24498484, ECO:0000269|PubMed:25650406, ECO:0000269|PubMed:2808364, ECO:0000269|PubMed:8027220, ECO:0000269|PubMed:8245018, ECO:0000269|PubMed:8345056, ECO:0000269|PubMed:8396144, ECO:0000269|PubMed:8550762, ECO:0000269|Ref.20}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Cortisol synthesis and secretion - Homo sapiens (human);Cushing,s syndrome - Homo sapiens (human);Steroid hormone biosynthesis - Homo sapiens (human);Prolactin signaling pathway - Homo sapiens (human);Ovarian steroidogenesis - Homo sapiens (human);17-Beta Hydroxysteroid Dehydrogenase III Deficiency;Steroidogenesis;Apparent mineralocorticoid excess syndrome;3-Beta-Hydroxysteroid Dehydrogenase Deficiency;21-hydroxylase deficiency (CYP21);Corticosterone methyl oxidase I deficiency (CMO I);Corticosterone methyl oxidase II deficiency - CMO II;Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase Deficiency;Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase Deficiency;Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH;Androgen and Estrogen Metabolism;17-alpha-hydroxylase deficiency (CYP17);Aromatase deficiency;11-beta-hydroxylase deficiency (CYP11B1);Androgen Receptor Network in Prostate Cancer;Glucocorticoid and Mineralcorticoid Metabolism;Oxidation by Cytochrome P450;Steroid Biosynthesis;Metapathway biotransformation Phase I and II;Phase I - Functionalization of compounds;Metabolism of lipids;Endogenous sterols;Cytochrome P450 - arranged by substrate type;Biological oxidations;Metabolism;Androgen biosynthesis;Metabolism of steroid hormones;Metabolism of steroids;C21-steroid hormone biosynthesis and metabolism;Glucocorticoid biosynthesis;androgen biosynthesis;glucocorticoid biosynthesis;superpathway of steroid hormone biosynthesis;Steroid hormones
(Consensus)
Recessive Scores
- pRec
- 0.806
Intolerance Scores
- loftool
- 0.455
- rvis_EVS
- -0.69
- rvis_percentile_EVS
- 14.97
Haploinsufficiency Scores
- pHI
- 0.0363
- hipred
- N
- hipred_score
- 0.309
- ghis
- 0.482
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.897
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cyp17a1
- Phenotype
- skeleton phenotype; renal/urinary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype; growth/size/body region phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan);
Gene ontology
- Biological process
- steroid biosynthetic process;androgen biosynthetic process;glucocorticoid biosynthetic process;sex differentiation;steroid metabolic process;sterol metabolic process;hormone biosynthetic process;progesterone metabolic process;oxidation-reduction process
- Cellular component
- endoplasmic reticulum;endoplasmic reticulum membrane;axon;neuronal cell body
- Molecular function
- steroid 17-alpha-monooxygenase activity;iron ion binding;oxygen binding;heme binding;17-alpha-hydroxyprogesterone aldolase activity